MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why BRVE Stock dropped -2.62% Today — RQD Quant Desk Flash
$21.19 -2.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $21.05
Braveheart Bio Inc. (BRVE) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.91B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $21.05 (-0.66%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BRVE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY BRVE SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 1.3% FCF Margin ($53.4M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$20.02-6.5% Next Q
39
Q2 (-2Q)Grade D$18.71+14.6% Next Q
42
Q3 (-1Q)Grade D$21.44-1.2% Next Q
44
CurrentGrade D$21.19-5.9% Hist 90D α
47
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BRVE Turnaround Squeeze
While BRVE currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.52) and Max Pain ($22.25) forces dealer call-delta covering toward $33.60.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BRVE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BRVE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BRVE Stock dropped -2.62% Today — RQD Quant Desk Flash
Braveheart Bio Inc. (BRVE) dropped -2.62% to $21.19, trading at 24% of its 52-week range ($17.86 – $32). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 24% of its 52-week range ($17.86 – $32) with RSI-14 at 49.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $21.19 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $53.4M annual free cash flow.
Live BRVE Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BRVE)
- ✓Walkthrough of BRVE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BRVE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.89%▼ DESCENDING CHANNEL
2026-10-30O $21.29H $21.77L $20.75C $21.19VOL 533.7K
RES: $26.82SUP: $14.04SMA50: $23.52SMA200: $24.23
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BRVE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BRVE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BRVE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BRVE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BRVE)
Health Care Rank #405 of 1016
⚔️ ADRX vs BRVE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BRVE vs. ADRX, TRAX, MLYS, ZBIO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Braveheart Bio Inc. (BRVE) ranks #405 by composite RQD confidence (47/100, grade D) and #271 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, BRVE leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. ADRX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with BRVE at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BRVE
ACTIVE
Braveheart Bio Inc. | D | 47/100 | — | — | — | -2.62% | $1.91B | Benchmark Subject |
| ADRX ADARx Pharmaceuticals Inc. | D+ | 52/100 | — | — | — | -0.56% | $1.91B | /adrx-vs-brve → |
| TRAX First Tracks Biotherapeutics Inc. | E | 33/100 | — | — | -35.0% | -1.08% | $1.90B | /trax-vs-brve → |
| MLYS Mineralys Therapeutics Inc. | D- | 43/100 | — | — | -28.4% | -0.65% | $1.88B | /mlys-vs-brve → |
| ZBIO Zenas BioPharma Inc. | D- | 39/100 | — | — | -35.0% | -0.04% | $1.87B | /zbio-vs-brve → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002131524In its most recent audited fiscal period (FY2025, filed 2025-12-31), Braveheart Bio Inc. (BRVE) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BRVE closed FY2025 with $89.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $89.3M | — |
3. BRVE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BRVE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Braveheart Bio Inc. (NASDAQ: BRVE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $21.19 (-2.62% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BRVE ranks #405 in composite RQD confidence.
How does BRVE compare to ADRX and TRAX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BRVE carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ADRX (ADARx Pharmaceuticals Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.91B) and TRAX (First Tracks Biotherapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.90B). Among the 5-stock peer group, BRVE leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BRVE?
Per BRVE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002131524), Braveheart Bio Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $89.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BRVE trading relative to its 50-day, 200-day, and 52-week technical levels?
BRVE last traded at $21.19 (-2.62% on volume of 304,135 shares), positioning the stock -9.91% below its 50-day simple moving average ($23.52) and -12.55% below its 200-day simple moving average ($24.23). Across its 52-week range of $17.86 to $32.00, BRVE sits at the 23.6% percentile with a 14-day RSI of 49.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.54 to $23.84).
BRVE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BRVE stock moving today?
Why BRVE Stock dropped -2.62% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.